ADMA Biologics, Inc. (OTCQB:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today reported financial and operational results for the third quarter ended September 30, 2013. Third quarter highlights and recent events include the following:
•Completed enrollment of Phase III study in Primary Immune Deficiency Diseases
Help employers find you! Check out all the jobs and post your resume.
